Director Joseph E. Gilliam filed an initial statement of beneficial ownership with the SEC on November 6, 2026, disclosing his securities holdings in 10x Genomics, Inc. as of the event date of October 28, 2026.
Key Highlights
- Reporting person: Joseph E. Gilliam, identified in the filing as a Director of 10x Genomics, Inc.
- Event date: The date of the event requiring the statement was October 28, 2026, according to the filing.
- Direct holdings: Gilliam reported direct beneficial ownership of 31 shares of Class A Common Stock.
- No derivative securities: The filing disclosed no derivative securities, including options, warrants, or convertible securities, in Table II.
- Signed by attorney-in-fact: The form was signed by Randy Wu as attorney-in-fact for Joseph E. Gilliam on November 6, 2026.
Gilliam's Initial Ownership Disclosure at 10x Genomics
Joseph E. Gilliam submitted a Form 3 - Initial Statement of Beneficial Ownership of Securities - filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. The filing was submitted on November 6, 2026, and relates to his becoming a reporting person at 10x Genomics, Inc. (NASDAQ:TXG), with the triggering event dated October 28, 2026, according to the document.
According to the filing, Gilliam directly beneficially owns 31 shares of Class A Common Stock. The ownership is listed as direct (D) in Table I, with no indirect holdings reported. Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, was left blank, indicating no such holdings were reported at the time of the filing.
The form was signed by Randy Wu as attorney-in-fact for Joseph E. Gilliam, with Exhibit 24.1 cited as the Power of Attorney. Gilliam's address of record is listed as c/o 10x Genomics, Inc., 6230 Stoneridge Mall Road, Pleasanton, California 94588, as stated in the filing.
What Was Disclosed
The filing is an initial beneficial ownership statement by Joseph E. Gilliam, a newly reporting director at 10x Genomics, Inc. It discloses direct ownership of 31 shares of Class A Common Stock and no derivative securities as of October 28, 2026.




Please wait processing your request...